Literature DB >> 22322208

Constant size, variable density aerosol particles by ultrasonic spray freeze drying.

Suzanne M D'Addio1, John Gar Yan Chan, Philip Chi Lip Kwok, Robert K Prud'homme, Hak-Kim Chan.   

Abstract

This work provides a new understanding of critical process parameters involved in the production of inhalation aerosol particles by ultrasonic spray freeze drying to enable precise control over particle size and aerodynamic properties. A series of highly porous mannitol, lysozyme, and bovine serum albumin (BSA) particles were produced, varying only the solute concentration in the liquid feed, c(s), from 1 to 5 wt%. The particle sizes of mannitol, BSA, and lysozyme powders were independent of solute concentration, and depend only on the drop size produced by atomization. Both mannitol and lysozyme formulations showed a linear relationship between the computed Fine Particle Fraction (FPF) and the square root of c(s), which is proportional to the particle density, ρ, given a constant particle size d(g). The FPF decreased with increasing c(s) from 57.0% to 16.6% for mannitol and 44.5% to 17.2% for lysozyme. Due to cohesion, the BSA powder FPF measured by cascade impaction was less than 10% and independent of c(s). Ultrasonic spray freeze drying enables separate control over particle size, d(g), and aerodynamic size, d(a) which has allowed us to make the first experimental demonstration of the widely accepted rule d(a)=d(g)(ρ/ρ(o))(1/2) with particles of constant d(g), but variable density, ρ (ρ(o) is unit density).
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322208     DOI: 10.1016/j.ijpharm.2012.01.048

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying.

Authors:  Suzanne M D'Addio; John Gar Yan Chan; Philip Chi Lip Kwok; Bryan R Benson; Robert K Prud'homme; Hak-Kim Chan
Journal:  Pharm Res       Date:  2013-07-27       Impact factor: 4.200

2.  Porous mannitol carrier for pulmonary delivery of cyclosporine A nanoparticles.

Authors:  Sharon Shui Yee Leung; Jennifer Wong; Heloisa Victorino Guerra; Kevin Samnick; Robert K Prud'homme; Hak-Kim Chan
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

3.  NanoXCT: a novel technique to probe the internal architecture of pharmaceutical particles.

Authors:  Jennifer Wong; Dexter D'Sa; Matthew Foley; John Gar Yan Chan; Hak-Kim Chan
Journal:  Pharm Res       Date:  2014-05-28       Impact factor: 4.200

4.  Development of Novel Chitosan Microcapsules for Pulmonary Delivery of Dapsone: Characterization, Aerosol Performance, and In Vivo Toxicity Evaluation.

Authors:  Manoel Ortiz; Denise Soledade Jornada; Adriana Raffin Pohlmann; Sílvia Stanisçuaski Guterres
Journal:  AAPS PharmSciTech       Date:  2015-02-05       Impact factor: 3.246

5.  Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance.

Authors:  Chune Zhu; Jianting Chen; Shihui Yu; Chailu Que; Lynne S Taylor; Wen Tan; Chuanbin Wu; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2020-07-24       Impact factor: 4.939

Review 6.  Therapeutic strategies based on polymeric microparticles.

Authors:  C Vilos; L A Velasquez
Journal:  J Biomed Biotechnol       Date:  2012-05-16

Review 7.  Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems.

Authors:  Piyush Mehta
Journal:  J Drug Deliv       Date:  2016-10-27

8.  Rapid Recovery of Clofazimine-Loaded Nanoparticles with Long-Term Storage Stability as Anti-Cryptosporidium Therapy.

Authors:  Jie Feng; Yingyue Zhang; Simon A McManus; Kurt D Ristroph; Hoang D Lu; Kai Gong; Claire E White; Robert K Prud'homme
Journal:  ACS Appl Nano Mater       Date:  2018-04-20

9.  Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids.

Authors:  Wanling Liang; Philip C L Kwok; Michael Y T Chow; Patricia Tang; A James Mason; Hak-Kim Chan; Jenny K W Lam
Journal:  Eur J Pharm Biopharm       Date:  2013-05-20       Impact factor: 5.571

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.